PERTZYE® (pancrelipase) is indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions.
Limitation of Use: PERTZYE is not interchangeable with other pancrelipase products.
Important Safety Information
Fibrosing colonopathy is associated with high-dose use of pancreatic enzyme replacement. Exercise caution when doses of PERTZYE® (pancrelipase) exceed 2,500 lipase units/kg body weight per meal (or greater than 10,000 lipase units/kg body weight per day).
To avoid irritation of oral mucosa, do not chew PERTZYE or retain in the mouth.
Hyperuricemia may develop. Consider monitoring uric acid levels in patients with hyperuricemia, gout, or renal impairment.
There is theoretical risk of viral transmission with all pancreatic enzyme products including PERTZYE.
Exercise caution when administering pancrelipase to a patient with a known allergy to proteins of porcine origin.
The most common adverse reactions (≥10% of patients treated with PERTZYE) are diarrhea, dyspepsia, and cough.
Please click here for full Prescribing Information and Medication Guide.References: 1. PERTZYE (pancrelipase) Prescribing Information. Bethlehem, PA: Digestive Care, Inc; May 2012. 2. Borowitz DS, Grand RJ, Durie PR. Use of pancreatic enzyme supplements for patients with cystic fibrosis in the context of fibrosing colonopathy. Consensus Committee. J Pediatr. 1995;127(5):681-684. 3. Manual of Clinical Enzyme Measurements. Freehold, NJ: Worthington Biomedical Corporation; 1972:1-56. 4. Ishiguro H, Steward MC, Naruse S, et al. CFTR functions as a bicarbonate channel in pancreatic duct cells. J Gen Physiol. 2009;133(3):315-326.